Finasteride
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Best fit for men trying to preserve DHT-sensitive scalp hair during natural, TRT, or testosterone-only contexts; also an established BPH drug.
The hard gate is informed consent around sexual, mood, suicidal-ideation, PSA-masking, gynecomastia, and pregnancy-handling risks before suppressing DHT.
Best fit for men trying to preserve DHT-sensitive scalp hair during natural, TRT, or testosterone-only contexts; also an established BPH drug. It is not a universal AAS hair-loss shield.
Post-Finasteride Syndrome (PFS): rare but potentially permanent sexual dysfunction, depression, suicidal ideation, and brain fog after discontinuation. 2025 EMA added suicidal ideation warning. Elevated estradiol and gynecomastia risk from loss of DHT's anti-estrogenic buffering. Teratogenic — absolute contraindication in pregnant women.
The only well-evidenced systemic DHT-reduction therapy for AGA on testosterone-based cycles. 83% of men showed no further hair loss at 2 years vs 28% placebo. Multi-decade safety database. Cost-optimized via Proscar 5 mg quartering (~1.25 mg at ~25% of Propecia's per-dose price).
High for testosterone-related AGA; complete non-responder rate approximately 20%. Effective only for testosterone-converted DHT-driven hair loss. Zero benefit against androgenic effects of trenbolone, primobolan, anavar, stanozolol. Worsens nandrolone-related hair loss (hard contraindication).
Intro
Finasteride is a synthetic azasteroid that functions as a mechanism-based (suicide) inhibitor of Type II 5-alpha-reductase (5αR2) — the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the prostate, scalp follicles, and genital skin. Unlike receptor antagonists, finasteride forms a stable, essentially irreversible covalent adduct with NADP+ inside the enzyme's active site, permanently inactivating each enzyme molecule it binds. New enzyme protein must be synthesized for activity to recover after discontinuation, explaining why its pharmacodynamic DHT suppression persists 24–48 hours despite a plasma half-life of only 4.7–7.1 hours.
The clinical rationale emerged from the landmark 1974 Dominican Republic observations (Imperato-McGinley et al.) of males born with inherited 5αR2 deficiency. These individuals lacked DHT from birth, showed no prostate growth, and never developed AGA despite normal testosterone — establishing DHT as the driver of both conditions, not testosterone itself. Finasteride (Proscar 5 mg) was FDA-approved for BPH in 1992; Propecia (1 mg) for AGA in males in 1997. Generic versions have been widely available since the mid-2000s.
On PepTutor, finasteride is primarily relevant to men using testosterone-based protocols (TRT or AAS cycles) who are genetically susceptible to AGA. DHT elevation from testosterone is the principal driver of AGA in these users; finasteride reduces this by suppressing serum DHT approximately 65–70% at 1 mg/day. Its use is specifically testosterone-mediated: it provides zero protection against hair loss from DHT-independent androgens (trenbolone, primobolan, anavar, stanozolol) and actively worsens hair loss when combined with nandrolone.
The compound carries a distinctive adverse effect profile centered on Post-Finasteride Syndrome (PFS) — a rare but potentially severe and permanent condition involving sexual dysfunction, neuropsychiatric symptoms, and physical changes. The 2025 European Medicines Agency ruling added suicidal ideation to finasteride's label, reflecting accumulating evidence that the neurosteroid disruption mechanism (reduced allopregnanolone → impaired GABA-A signaling) can produce serious psychiatric consequences in a subset of users. PFS must not be dismissed as nocebo; it is pharmacologically real and regulatory-recognized.
Observed Effects
PRIMARY HAIR EFFECTS: JAMA Dermatology systematic review (n=3,927): finasteride 1 mg produced RR of hair improvement 1.81 at 12 months, 1.71 at 24 months vs placebo.
83% of men showed no further hair loss at 2 years vs 28% placebo. Vertex improvement: approximately 48% at 1 year, 66% at 2 years. Acta Dermato-Venereologica meta-analysis: hair count increases of +9.42% at 12 months, +24.3% at 24 months. Hair count gains are progressive with continuous use — maximum benefit observed at approximately 2 years.
DHT SUPPRESSION: serum DHT reduced approximately 65–70% at 1 mg/day; approximately 70–75% at 5 mg/day. Both doses produce comparable scalp DHT suppression (>70% locally) making them clinically equivalent for AGA. Serum testosterone rises 10–15% as the 5αR clearance route is blocked. PSA levels decrease approximately 50% (requires doubling for clinical screening interpretation).
HAIR REGROWTH TIMELINE: Initial shedding months 1–2 (expected — follicles transitioning phases; do not discontinue). Stabilization of active loss months 3–6. Visible improvement in texture and thickness months 6–12. Measurable density gains and some miniaturized follicle recovery months 12–24. Maximum response at approximately 2 years.
BPH EFFECTS: Prostate volume reduction approximately 20–30% at 12–24 months. Acute urinary retention risk reduced approximately 50–57% over 2–4 years (BMC Urology, n=8,820). IPSS symptom score improvement confirmed in Cochrane review.
NON-RESPONDERS: approximately 20% of users show no meaningful response despite adherent use — hair loss continues at baseline trajectory. Non-response is more likely with advanced AGA (NW5–7), late start (extensive miniaturization already present), or DHT-independent androgenic compounds on cycle.
NOT OBSERVED: No body composition benefit (no effect on muscle mass, fat distribution, or insulin sensitivity). No protection against hair loss from tren, primo, anavar, winstrol, masteron, or nandrolone. No efficacy in female AGA (postmenopausal women — failed RCT primary endpoints). Hair returns to natural loss trajectory on discontinuation — no permanent cure, only suppression while maintained.
Field Reports
Long-term success reports cluster around early starts, consistent use, and combination with minoxidil or other non-systemic hair supports.
Users who begin before extensive miniaturization tend to report the best preservation. TRT users who monitor DHT and estradiol often describe finasteride as manageable when it is kept in the testosterone-mediated lane.
Negative reports cluster around delayed libido decline, erectile changes, mood flattening, anxiety or depression, brain fog, and persistent symptoms after discontinuation. Delayed-onset side effects are an important pattern because a short early tolerance window does not rule out later problems.
Initial shedding during the first months is commonly reported and can be mistaken for treatment failure. The nandrolone failure pattern is also repeatedly reported: adding finasteride to nandrolone-containing cycles can accelerate hair loss in a way that matches the DHN mechanism. Topical users often report a better systemic-tolerability tradeoff, while oral users report stronger DHT suppression and sometimes more side effects.
Community Consensus
Finasteride is understood in the AAS community with unusually specific boundaries: it is a testosterone-mediated hair-protection tool, not a universal androgen hair-loss shield.
The nandrolone contraindication, the lack of utility for DHT-independent androgens, and the topical-versus-oral tradeoff are all part of the practical field read.
Community sentiment is genuinely split around PFS. Many long-term users report stable hair preservation without meaningful adverse effects; a smaller but serious group report prolonged sexual, mood, and cognitive symptoms after discontinuation. Both signals matter. The 2025 EMA suicidal-ideation warning makes the severe end harder to dismiss, while nocebo and expectation effects still complicate ordinary side-effect reporting.
The practical consensus is informed consent plus monitoring: baseline hormones, follow-up DHT/E2 checks, PSA-context disclosure, and a low threshold to stop when persistent sexual or psychological symptoms appear. Cost-cutting tablet practices and named creator debates are less important than these clinical boundaries.
Risks & Monitoring
SEXUAL ADVERSE EFFECTS: Decreased libido (1.8% vs 1.3% placebo at 1 mg/day). Erectile dysfunction (RR 2.22; NNH 82.1 at 1 mg — higher at 5 mg per Journal of Sexual Medicine meta-analysis).
Decreased ejaculate volume (3–6% in BPH trials). Overall NNH for any sexual side effect at 12 months = 14 (one in 14 treated men experiences a sexual adverse effect their untreated counterpart would not). DHT contributes directly to erectile quality, rigidity, and libido; the T:DHT imbalance created by finasteride (T elevated, DHT suppressed) impairs both even when total testosterone remains normal.
ESTROGEN EFFECTS: Finasteride removes DHT's natural anti-estrogenic buffering — DHT acts as a reversible aromatase inhibitor and blocks estrogen-mediated gene transcription at breast tissue. Net effect: (1) more testosterone aromatizes to estradiol; (2) the remaining estradiol is more effective at breast tissue without DHT competition. Both absolute E2 and estrogenic sensitivity increase. Gynecomastia: ~0.5–1.2% depending on dose. Men managing AI use alongside testosterone must recalibrate after adding finasteride — E2 often rises. 'Not only do 5αR inhibitors increase serum estradiol, they also make you more susceptible to estrogenic side effects compared to men who have normal DHT levels' (experienced community educator).
NEUROPSYCHIATRIC EFFECTS: Depression and anxiety confirmed at elevated rates vs controls in multiple observational cohort studies. Mechanistic basis: 5αR also produces neurosteroids — finasteride suppresses allopregnanolone (a positive GABA-A allosteric modulator). Reduced allopregnanolone shifts GABA-A tone from anxiolytic toward anxiogenic. 'When allopregnanolone is high, GABA gets synthesized and has an anxiolytic effect; below a threshold, it's anxiogenic rather than anxiolytic' (community educator). Brain fog (cognitive slowing, difficulty concentrating) is among the most frequently reported neurological complaints. The 2025 EMA updated labeling to include suicidal ideation — reflecting accumulating case reports and the established neurosteroid mechanism.
POST-FINASTERIDE SYNDROME (PFS): PFS must not be dismissed as nocebo. While blinded studies show lower adverse event rates when subjects don't know they're taking finasteride (real nocebo component), the syndrome is FDA-recognized (2012 persistent sexual effects warning), EMA-recognized (2025 suicidal ideation warning), and mechanistically explained (NADP-dihydrofinasteride adduct, allopregnanolone suppression, CNS penetration). The PFS triad: (1) persistent sexual dysfunction (low libido, ED, reduced ejaculate) not resolving after discontinuation; (2) neuropsychiatric symptoms (depression, anxiety, suicidal ideation, brain fog); (3) physical symptoms (muscle weakness, skin changes). 'There is no known cure (no consistent cure), and the effects can last years' (independent practitioner source). Stop immediately at first signs of persistent sexual or psychological effects.
DELAYED ONSET: Adverse effects including libido decline can develop after years of apparently problem-free use — documented pattern of sides emerging at years 6–7 after 6 years of tolerance. The '3-month safety screening' is insufficient; annual monitoring and ongoing awareness are required.
OTHER ADVERSE EFFECTS: PSA masking (approximately 50% reduction — doubles prostate cancer screening requirement). Testicular ache at higher doses (generally resolves with dose reduction). Hypersensitivity reactions (rash, angioedema — rare, post-marketing). Semen parameter changes (reduced volume, possible motility effects — reversible within 3–6 months on discontinuation).
MANAGEMENT IF SIDES EMERGE: Stop finasteride — clears within 4–5 days. Comprehensive bloodwork: total T, free T, DHT, E2 sensitive, SHBG, DHEA-S, plus DUTCH saliva test including allopregnanolone if neuropsychiatric symptoms present. Rule out comorbid causes (caloric deficit, stress, pornography overuse, micronutrient deficiency). For persistent PFS: work with hormone specialist; NAD+ supplementation (NMN 500–1200 mg/day or IV NAD+ 250–500 mg weekly) is the most consistently reported community adjunct — theoretical basis is the NADPH co-factor requirement for 5αR enzyme function.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establishes your pre-finasteride DHT level. Without baseline, you cannot interpret changes on therapy or detect over-suppression. Essential reference point for dosing calibration.
Finasteride raises serum T 10–15% by blocking the 5αR clearance route. Baseline T required to contextualize the T:DHT ratio shift and separate libido effects of elevated T from those of suppressed DHT.
Finasteride removes DHT's anti-estrogenic buffering — E2 rises and estrogenic side effects (gynecomastia, water retention, mood) become more likely. LC-MS sensitive assay required — immunoassay is unreliable at physiologic male E2 levels. AI dosing must be recalibrated after starting finasteride.
SHBG determines the free fraction of testosterone and DHT. Rising T from finasteride may be partially offset by SHBG changes. Context needed for interpreting free DHT and free T values.
Finasteride suppresses PSA approximately 50%. Establishing baseline enables accurate interpretation of future PSA results — all subsequent on-finasteride PSA must be doubled for clinical cancer screening. Without baseline, finasteride-suppressed PSA could mask early prostate pathology. Inform all physicians ordering PSA that you are on finasteride.
Check at 6–8 weeks after starting. Confirm DHT suppressed but NOT below lower reference range. Confirm T and E2 acceptable. Dose-calibration check: if DHT below lower reference range, reduce dose; if insufficient suppression and loss continues, increase dose or switch to topical. Target: DHT middle to top of reference range, not crushed.
Every 3–6 months during active testosterone cycles; every 6–12 months for stable long-term standalone AGA use. Enables early detection of creeping E2 elevation, DHT over-suppression, or PSA drift. Reduces to 6–12 month intervals for stable, long-term users with no adverse effects.
If persistent sexual dysfunction, depression, anxiety, or brain fog develop after stopping finasteride. DUTCH provides comprehensive neurosteroid picture including allopregnanolone — the GABA-A modulator whose suppression underlies PFS neuropsychiatric symptoms. Standard blood panels do not measure allopregnanolone. Essential diagnostic tool for suspected PFS.
Avoid With
Do not combine Finasteride with the following. Sorted highest-severity first.
Why:Nandrolone undergoes 5αR reduction to dihydronandrolone (DHN), which has substantially lower androgenic activity than nandrolone itself — 5αR reduction deactivates nandrolone. Finasteride blocks this conversion, leaving nandrolone (stronger hair-loss activity) as the predominant form. 'Finasteride is a 5αR inhibitor. Nandrolone 5α-reduces into DHN, which is a compound with very weak hair loss action. However, when nandrolone is prevented from 5α-reducing into DHN because of finasteride, it is stuck as nandrolone, which has very strong hair loss action.' (independent practitioner source)
What to do:Absolute contraindication at any dose — any finasteride dose worsens nandrolone-mediated AGA by blocking the protective DHN conversion. Multiple community sources confirm accelerated hair loss in users who combined these. Do not use.
Why:These compounds do not undergo meaningful 5αR reduction to androgenic metabolites; their androgenic activity is intrinsic. Finasteride has zero protective effect against hair loss from these compounds. Using finasteride alongside them provides no benefit while exposing the user to PFS risk and the T:DHT hormonal imbalance.
What to do:Not a pharmacological danger like nandrolone, but a critical therapeutic irrelevance warning. Finasteride is frequently misunderstood as a general AAS hair protection drug — it is not.
Why:Oral ketoconazole is a potent CYP3A4 inhibitor; finasteride is primarily metabolized via CYP3A4. Co-administration substantially increases finasteride plasma concentrations, amplifying both efficacy and adverse effect risk.
What to do:Topical ketoconazole shampoo (2%) does not carry this interaction and is safe and recommended alongside finasteride. Only oral antifungal ketoconazole medication (prescription systemic fungal treatment) presents the CYP3A4 interaction.
Why:Finasteride removes DHT's natural aromatase-inhibiting and anti-estrogenic buffering. Adding finasteride to a testosterone + AI protocol shifts the estrogen balance: E2 rises, and AI dose that was appropriate before may now be insufficient. The hair/gynecomastia/acne triangle management becomes more complex.
What to do:Not a contraindication — a management complexity requiring bloodwork-guided AI recalibration. Check E2 at 6–8 weeks after adding finasteride and adjust AI dose accordingly.
Protocols By Goal
AGA ON TRT (100–200 mg/week testosterone): 1 mg/day oral or topical 0.1%. Monitor DHT, T, E2 sensitive, SHBG at 6–8 weeks. Target DHT low-normal range — not below lower reference. Recalibrate AI dosing (E2 often rises after adding finasteride). Continue indefinitely.
AGA ON AAS CYCLE (testosterone base only): 1–2 mg/day oral depending on testosterone dose. Start at cycle initiation. Confirm with DHT bloodwork at week 6. NEVER add if cycle contains nandrolone. Zero benefit for tren/primo/anavar/winstrol cycles — do not use.
AGA IN NON-AAS USERS: 1 mg/day oral (or cautious topical protocol). Start early — respond better at NW2–3 than NW5–7. Combine with topical minoxidil for superior vertex outcomes. Add ketoconazole 2% shampoo 2–3×/week. Annual monitoring.
HAIR-SAFE AAS APPROACH (hair is top priority): If hair preservation supersedes all else, consider nandrolone-only protocols (nandrolone is the only mainstream AAS compound that is technically hair-safe — 5αR converts it to weaker DHN). Alternatively: topical ketoconazole + minoxidil without systemic 5ARIs. RU-58841 topical (research chemical) provides local AR blockade without systemic DHT suppression.
BPH MANAGEMENT: 5 mg/day oral. Prostate volume reduction at 12–24 months. PSA must be doubled for screening interpretation. Combine with alpha-1 blocker (tamsulosin) for symptom relief if needed.
PFS RECOVERY: Stop finasteride. Comprehensive bloodwork + DUTCH test including allopregnanolone. Rule out comorbid lifestyle factors (caloric deficit, stress, relationship dysfunction, pornography). If persistent: NAD+ supplementation (IV 250–500 mg weekly or oral NMN/NR 500–1200 mg/day). For severe cases with active AAS use: temporary testosterone dose increase may help restore DHT as finasteride clears. Consult hormone specialist familiar with neurosteroid disruption.
SIDES-SENSITIVE USERS: Start topical only. Monitor DHT at 6 weeks. If hair loss progresses despite topical maximum dose, consider RU-58841 (different mechanism) or dutasteride topical rather than oral finasteride. Accept that some users must choose between hair and preserved DHT biology.
Dosing Details
Reported finasteride practice generally separates pharmaceutical-label use from community hair-preservation use.
The established oral reference points are 1 mg/day for male AGA and 5 mg/day for BPH; community hair-loss practice also includes lower oral exposures such as 0.25-0.5 mg/day, alternate-day dosing, and topical finasteride when users are trying to reduce systemic DHT suppression. Higher oral exposures above the AGA label dose are reported mainly in testosterone-cycle contexts, but they are empirical rather than clinically validated.
Topical finasteride is commonly discussed as the cautious entry point because scalp DHT suppression can be meaningful while serum DHT reduction is lower than oral use. Oral finasteride remains the better-studied route. Any dose change should be judged against hair trajectory, sexual/mood tolerability, estradiol symptoms, and DHT bloodwork rather than copied from bodybuilding shorthand.
In AAS contexts, the useful boundary is compound-specific: reported use is testosterone-only or testosterone-base hair protection. It is not useful for trenbolone, primobolan, anavar, stanozolol, or masteron hair loss, and it is a hard avoid with nandrolone because blocking 5-alpha-reduction can worsen the DHN pathway hair profile. Stopping during an active high-testosterone context is also treated cautiously because DHT rebound shedding can occur.
Stacks & Alternatives
Evidence-based complementary combination. Finasteride addresses DHT-driven follicle miniaturization; minoxidil promotes scalp blood flow and prolongs anagen phase independently. Multiple RCTs confirm combination superiority over either alone. Community consensus: synergistically better, especially for vertex density. Can be combined in a single topical solution with finasteride (Minoxfin formula).
Topical anti-androgenic activity at scalp via AR modulation. Non-systemic at shampoo concentrations. Additive to finasteride via different mechanism. Community-standard baseline alongside finasteride. Use 2–3×/week. Note: ORAL ketoconazole (CYP3A4 inhibitor) significantly increases finasteride plasma levels — topical shampoo is safe, oral antifungal medication is not.
Topical androgen receptor antagonist — blocks DHT/T at scalp AR without reducing systemic DHT. Preferred by men who want to preserve systemic DHT biology (libido, erections, neurosteroids) while blocking scalp androgenic activity. Mechanistically complementary to finasteride (receptor vs enzyme). Research chemical — no pharmaceutical standardization.
Mechanical induction of growth factors via microtrauma. Enhances penetration and efficacy of topical finasteride and minoxidil. Critical timing: do NOT apply topicals within 24 hours of microneedling — disrupted skin barrier dramatically increases systemic absorption, defeating the low-systemic rationale for topical use.
Finasteride is most commonly used specifically on testosterone protocols. Does not reduce testosterone's anabolic effects. Recalibrate estrogen management after adding finasteride: E2 often rises (more T available for aromatization, DHT's anti-estrogenic buffering removed). Never combine with nandrolone-containing cycles.
Alternatives
Stack Cost
High tax: finasteride can be a high-value hair-preservation tool, but it consumes a DHT/neurosteroid lane, changes estrogen handling, masks PSA, carries rare durable PFS risk, and has one hard AAS-specific contraindication with nandrolone.
The article repeatedly frames finasteride as systemic DHT suppression rather than a local cosmetic add-on: serum DHT falls about 65-70% at 1 mg/day, testosterone rises 10-15%, and E2/gynecomastia management can change because DHT's anti-estrogenic buffering is reduced.
adverseEffects and mechanisms connect finasteride to reduced allopregnanolone/GABA-A signaling, depression/anxiety reports, brain fog, PFS, and the 2025 EMA suicidal-ideation warning. The issue is rare, but the article treats the durable neuropsychiatric tail as real.
stackingConflicts marks nandrolone as a hard avoid because blocking nandrolone's 5-alpha reduction prevents conversion to weaker DHN and can worsen hair loss. It also flags therapeutic irrelevance with trenbolone, primobolan, oxandrolone, stanozolol, and masteron.
recommendedPanels requires baseline and 6-8 week DHT/T/E2 checks for dose calibration, plus PSA interpretation rules because finasteride suppresses PSA about 50%. This is especially relevant when the user is also managing testosterone, AIs, or prostate screening.
womenConsiderations treats pregnancy exposure as an absolute contraindication because DHT is required for male fetal genital development, and broken/crushed tablet handling can matter in households with pregnant or potentially pregnant women.
- ·Counts as a DHT-suppression and neurosteroid-disruption lane; do not stack casually with dutasteride or other 5-alpha-reductase inhibitors unless deeper suppression is the explicit goal.
- ·Works for testosterone-converted DHT hair loss, not DHT-independent androgen load from trenbolone, primobolan, oxandrolone, stanozolol, or masteron.
- ·Avoid entirely with nandrolone-containing protocols because the article identifies this as the single most important AAS-specific contraindication.
- ·When used with testosterone and aromatase inhibitors, treat E2 recalibration as part of the protocol rather than an afterthought.
- ·For drug-tested athletes, WADA masking-agent status makes the stack tax effectively prohibitive.
- ·Baseline DHT, total/free testosterone, sensitive estradiol, SHBG, and PSA before systemic use.
- ·Repeat DHT/T/E2 at 6-8 weeks to confirm DHT is reduced but not crushed below range.
- ·PSA interpretation discipline: future PSA values need finasteride context and often doubling for screening interpretation.
- ·A clear stop rule for persistent sexual dysfunction, mood deterioration, suicidal ideation, or brain fog.
- ·Household handling rules for pregnant or potentially pregnant women, especially around broken tablets.
Finasteride is cheap, oral, FDA-approved, and widely used, but the article's ordinary-use downside is not just inconvenience: systemic DHT suppression can create sexual, mood, estrogen, PSA, and rare durable PFS problems. AAS-cycle use, psychiatric history, fertility/pregnancy household concerns, or nandrolone exposure move it out of beginner territory.
- ·Using nandrolone, NPP, or Deca
- ·History of severe depression, suicidal ideation, persistent sexual dysfunction, or suspected PFS
- ·Running supraphysiologic testosterone with active AI management
- ·Drug-tested under WADA rules
- ·Household includes a pregnant or potentially pregnant partner who may handle broken tablets
Plasma clearance is short, but enzyme recovery depends on new 5-alpha-reductase synthesis and hair benefits reverse after stopping. Most side effects should improve after discontinuation, while the article preserves a rare persistent PFS tail and warns that stopping during a testosterone cycle can trigger DHT rebound shedding.
- ·Return to natural hair-loss trajectory within months
- ·DHT rebound shedding if stopped abruptly while testosterone remains high
- ·Persistent sexual, mood, or cognitive symptoms in suspected PFS cases
- ·Need to re-interpret PSA after discontinuation
- ·Loss of the cost/benefit logic if adherence is inconsistent
Do not combine finasteride with nandrolone-containing protocols. The article treats this as an absolute contraindication, not a dose-adjustment problem.
Start at the minimum effective dose, avoid crushing DHT below range, and stop promptly if persistent sexual or psychological symptoms appear. Suicidal ideation is an urgent medical red flag.
Check sensitive estradiol 6-8 weeks after adding finasteride and recalibrate testosterone/AI management with labs rather than symptoms alone.
Tell every clinician ordering PSA that finasteride is in use; the article states PSA is suppressed about 50% and needs adjusted interpretation.
stackingConflicts explains that blocking nandrolone's conversion to weaker DHN can worsen scalp androgenic pressure.
womenConsiderations marks fetal male genital-development risk as the central irreversible exposure concern.
adverseEffects preserves the EMA suicidal-ideation warning and the neurosteroid/PFS mechanism.
quickSummary and practicalConsiderations state finasteride is prohibited as a masking agent.
Practical Setup
The practical first step is deciding whether systemic DHT suppression is worth the tradeoff. Finasteride can preserve DHT-sensitive scalp hair, but DHT also participates in libido, erectile quality, mood, neurosteroid tone, and estrogen buffering.
PSA communication is mandatory: finasteride can reduce PSA by roughly 50%, so clinicians interpreting prostate screening need to know it is in use. Pregnant women or women who may become pregnant should not handle crushed, broken, or dissolved tablets because fetal male genital development depends on DHT.
In AAS contexts, the most important boundary is never combining finasteride with nandrolone. It also does not protect against hair loss from trenbolone, primobolan, anavar, stanozolol, or masteron. Track monthly scalp photos, sexual function, mood, breast-tissue sensitivity, and DHT/E2 labs when available. Stop and seek clinician input if persistent sexual, mood, or suicidal-ideation symptoms appear.
Mechanism Deep Dive
PRIMARY MECHANISM — SUICIDE INHIBITION: Finasteride functions as a mechanism-based (suicide) inhibitor of Type II 5-alpha-reductase (5αR2).
The compound enters the enzyme's active site, where it undergoes a partial catalytic reaction with NADP+ to form a stable NADP-dihydrofinasteride adduct. This adduct is thermodynamically stable under physiological conditions — neither the NADP+ co-factor nor finasteride can be released. Each enzyme molecule that binds finasteride is permanently inactivated. New enzyme protein must be synthesized via normal protein turnover for 5αR activity to recover, explaining why the pharmacodynamic effect (DHT suppression) persists 24–48 hours per dose despite the compound's 4.7–7.1 hour plasma half-life.
ISOFORM SPECIFICITY: Three 5αR isoforms exist with distinct tissue distributions: Type I (5αR1) in skin, liver, and brain; Type II (5αR2) in prostate, scalp follicles, and genital skin; Type III (5αR3) in multiple tissues. Finasteride primarily inhibits 5αR2 (and partially 5αR3). Dutasteride inhibits all three. Selective 5αR2 inhibition means finasteride has a smaller neurosteroid disruption footprint than dutasteride — particularly sparing some 5αR1-mediated allopregnanolone production in the brain — which partly explains why dutasteride may have more pronounced CNS effects.
DHT PATHWAY: 5αR2 catalyzes the NADPH-dependent reduction of testosterone to DHT. DHT has approximately 5× greater androgen receptor (AR) binding affinity than testosterone. In genetically susceptible scalp follicles (overexpressing 5αR2 and AR), DHT drives progressive follicle miniaturization by shortening the anagen growth phase. In the prostate, DHT is the primary driver of glandular growth and PSA production. Finasteride reduces serum DHT approximately 65–70% at 1 mg/day; local scalp DHT suppression exceeds 70% at both 1 mg and 5 mg.
NEUROSTEROID PATHWAY: 5αR also reduces progesterone to dihydroprogesterone (DHP) and DHDOC, substrates for allopregnanolone synthesis by 3α-hydroxysteroid dehydrogenases. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors — the primary inhibitory neurotransmitter system. Adequate allopregnanolone enhances GABA-A inhibitory tone (anxiolytic, mood-stabilizing); suppression shifts this tone toward anxiogenic and pro-depressive states. 'When allopregnanolone is high, GABA gets synthesized and has an anxiolytic effect; below a threshold, it's anxiogenic rather than anxiolytic' (community educator). This neurosteroid disruption is the accepted mechanistic basis for PFS neuropsychiatric symptoms and underlies the 2025 EMA suicidal ideation warning.
ESTROGEN INTERACTION: DHT acts as a reversibly-binding aromatase inhibitor, competing with testosterone for the aromatase active site, and also blocks estrogen-mediated gene transcription at estrogen receptors in breast tissue. Finasteride eliminates both protections: (1) more testosterone is available for aromatization → E2 rises; (2) reduced DHT anti-estrogenic buffering → breast tissue more sensitive to existing E2. Net: both absolute E2 and estrogenic tissue sensitivity increase, amplifying gynecomastia and estrogenic side effect risk.
NANDROLONE INTERACTION — DEACTIVATION PATHWAY: Nandrolone undergoes 5αR reduction to dihydronandrolone (DHN), which has substantially lower androgenic activity — unlike testosterone's activation to potent DHT, nandrolone's 5αR conversion is a deactivation. Finasteride blocks this conversion, leaving nandrolone (higher androgenic potency for scalp) as the predominant metabolite. This mechanistically explains the catastrophic AGA worsening from finasteride + nandrolone co-administration.
NAD/NADPH CO-FACTOR: The 5αR enzyme requires NADPH for catalysis. The NADP-dihydrofinasteride adduct permanently sequesters both the active site and the co-factor, rendering the enzyme non-functional until protein turnover provides new enzyme molecules. Community researchers and practitioners have proposed that age-related NAD+ decline may impair enzyme recovery after finasteride discontinuation — explaining why older men appear more vulnerable to persistent PFS and why NAD+ precursor supplementation (NMN/NR, IV NAD+) has theoretical basis as a PFS recovery adjunct.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Finasteride 1 mg improved hair-growth outcomes versus placebo at 12 and 24 months, with RR 1.81 at 12 months and 1.71 at 24 months.
Applies best to male AGA, not female AGA or hair loss from DHT-independent anabolic compounds.
83% of men had no further hair loss at 2 years versus 28% on placebo.
Maintenance requires continued use; stopping returns hair loss toward the natural trajectory.
Serum DHT falls about 65-70% at 1 mg/day and about 70-75% at 5 mg/day, while scalp DHT suppression is similar enough that both doses are clinically comparable for AGA.
Higher systemic dose does not proportionally improve scalp effect but can increase adverse-effect burden.
PSA decreases about 50% on finasteride and must be adjusted for prostate screening interpretation.
This is a screening-interpretation issue, not an efficacy claim; clinicians need medication context.
Sexual adverse effects include decreased libido, erectile dysfunction, and ejaculate-volume changes; the article cites ED RR 2.22 and NNH 82.1 at 1 mg, plus NNH 14 for any sexual side effect at 12 months.
Nocebo contributes to some reports, but the article preserves persistent sexual effects as a recognized rare tail.
Finasteride reduces prostate volume about 20-30% at 12-24 months and reduces acute urinary-retention risk about 50-57% over 2-4 years.
BPH efficacy uses the 5 mg Proscar dose; this is separate from the 1 mg AGA use case.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.